• About us
• Contact

Advertisement

Organisation › Details

Abingworth Clinical Co-Development Fund 2 (ACCD 2)

Abingworth is a leading transatlantic life sciences investment firm with over $2 billion under management. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top calibre management teams building world-class companies. Since 1973, Abingworth has invested in over 179 life science companies, leading to 46 M&As and 73 IPOs. Our therapeutic focused investments fall into three categories: seed and early-stage, development stage, and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston. *

 

	Start	2021-05-10 closing, final
	Group	Carlyle (Group)
	Industry	pharmaceutical
	Industry 2	biopharmaceutical
	Person	Cornwall, James (Abingworth 202105– Partner to work on ACCD 2 before Nuvelution + Quintiles)
	Region	London, Greater London
	Country	United Kingdom (GB)
	City	n. a.
		Address record changed: 2022-04-12
Basic data	Employees	n. a.
	Currency	USD
	Annual sales	582,000,000 (fund size at final closing (2021) 2021-05-10)
		* Document for »About Section«: Carlyle Group, The. (4/11/22). "Press Release: Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth". New York, NY.
		Record changed: 2023-10-31

Advertisement

More documents for Carlyle (Group)

• [1] Abingworth LLP. (10/30/23). "Press Release: Abingworth Raises $356 Million for New Clinical Co-Development Co-Investment Fund (CCD-CIF)". London & New York, NY....
• [2] Carlyle Group, The. (4/11/22). "Press Release: Carlyle Expands Leading Healthcare Franchise with Agreement to Acquire Life Sciences Investment Firm Abingworth". New York, NY....
• [3] Glycomine, Inc.. (12/17/21). "Press Release: Glycomine Closes $68 Million Series B to Advance into Clinical Trials a Novel Treatment for PMM2-CDG, a Rare Glycosylation Disease". San Carlos, CA....
• [4] Anjarium Biosciences AG. (9/16/21). "Press Release: Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies". Schlieren....
• [5] Abingworth LLP. (9/15/21). "Press Release: Abingworth Strengthens Investment Team with New Appointments in the US and UK". London....
• [6] Inova Software SAS. (7/1/21). "Press Release: Carlyle Partners with Inova. Growth Equity Transaction to Support Inova’s Ambition to Become the Leading Platform for Life Science Collaborations". Lyon....
• [7] Abingworth LLP. (5/10/21). "Press Release: Abingworth Raises $582 Million for New Clinical Co-Development Fund – ACCD 2". London....
• [8] Abingworth LLP. (2/3/21). "Press Release: Abingworth Raises $465m for New Life Sciences Fund Abingworth Bioventures 8". London....
• [9] GHO Capital Partners LLP. (6/3/20). "Press Release: GHO Capital Acquires X-Chem, a Leading Drug Discovery Service Provider". London....
• [10] Emulate, Inc.. (3/19/20). "Press Release: Emulate, Inc. Appoints Jim Corbett as Chief Executive Officer and Martin Madaus, PhD, as Executive Chairman". Boston, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.